.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Boehringer Ingelheim
Chinese Patent Office
Federal Trade Commission
Daiichi Sankyo
Cantor Fitzgerald
US Army
Cipla
Harvard Business School

Generated: September 26, 2017

DrugPatentWatch Database Preview

Concordia Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for CONCORDIA PHARMS INC, and what generic alternatives to CONCORDIA PHARMS INC drugs are available?

CONCORDIA PHARMS INC has twelve approved drugs.

There are two US patents protecting CONCORDIA PHARMS INC drugs.

There are sixty patent family members on CONCORDIA PHARMS INC drugs in thirty-eight countries.

Summary for Applicant: Concordia Pharms Inc

Patents:2
Tradenames:13
Ingredients:11
NDAs:12
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Concordia Pharms Inc
LANOXIN
digoxin
TABLET;ORAL020405-006Sep 30, 1997DISCNNoNo► Subscribe► Subscribe► Subscribe
Concordia Pharms Inc
ORAPRED ODT
prednisolone sodium phosphate
TABLET, ORALLY DISINTEGRATING;ORAL021959-001Jun 1, 2006ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Concordia Pharms Inc
KAPVAY
clonidine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022331-004Sep 28, 2010DISCNYesNo► Subscribe► Subscribe► Subscribe
Concordia Pharms Inc
JENLOGA
clonidine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022331-002May 25, 2010DISCNYesNo► Subscribe► Subscribe► Subscribe
Concordia Pharms Inc
LANOXIN
digoxin
TABLET;ORAL020405-005Sep 30, 1997DISCNNoNo► Subscribe► Subscribe► Subscribe
Concordia Pharms Inc
PLAQUENIL
hydroxychloroquine sulfate
TABLET;ORAL009768-001Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe
Concordia Pharms Inc
LANOXIN
digoxin
TABLET;ORAL020405-001Sep 30, 1997RXYesNo► Subscribe► Subscribe► Subscribe
Concordia Pharms Inc
NILANDRON
nilutamide
TABLET;ORAL020169-001Sep 19, 1996DISCNNoNo► Subscribe► Subscribe► Subscribe
Concordia Pharms Inc
ORAPRED ODT
prednisolone sodium phosphate
TABLET, ORALLY DISINTEGRATING;ORAL021959-003Jun 1, 2006ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Concordia Pharms Inc
JENLOGA
clonidine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022331-001Sep 30, 2009DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Concordia Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Concordia Pharms Inc
JENLOGA
clonidine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022331-001Sep 30, 2009► Subscribe► Subscribe
Concordia Pharms Inc
UROXATRAL
alfuzosin hydrochloride
TABLET, EXTENDED RELEASE;ORAL021287-001Jun 12, 2003► Subscribe► Subscribe
Concordia Pharms Inc
ORAPRED ODT
prednisolone sodium phosphate
TABLET, ORALLY DISINTEGRATING;ORAL021959-003Jun 1, 2006► Subscribe► Subscribe
Concordia Pharms Inc
KAPVAY
clonidine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022331-004Sep 28, 2010► Subscribe► Subscribe
Concordia Pharms Inc
KAPVAY
clonidine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022331-003Sep 28, 2010► Subscribe► Subscribe
Concordia Pharms Inc
ORAPRED ODT
prednisolone sodium phosphate
TABLET, ORALLY DISINTEGRATING;ORAL021959-001Jun 1, 2006► Subscribe► Subscribe
Concordia Pharms Inc
JENLOGA
clonidine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022331-002May 25, 2010► Subscribe► Subscribe
Concordia Pharms Inc
ORAPRED ODT
prednisolone sodium phosphate
TABLET, ORALLY DISINTEGRATING;ORAL021959-002Jun 1, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for CONCORDIA PHARMS INC drugs

Drugname Dosage Strength Tradename Submissiondate
clonidine hydrochloride
Extended-release Tablets0.1 mg and 0.2 mg
KAPVAY
3/4/2011
clonidine hydrochloride
Extended-release Tablets0.1 mg and 0.2 mg
JENLOGA
3/4/2011
prednisolone sodium phosphate
Orally Disintegrating Tablets10 mg, 15 mg and 30 mg
ORAPRED
7/22/2010
alfuzosin hydrochloride
Extended-release Tablets10 mg
UROXATRAL
6/12/2007

International Patent Family for Concordia Pharms Inc Drugs

Country Document Number Estimated Expiration
Spain2159400► Subscribe
Bulgaria63768► Subscribe
Portugal938318► Subscribe
Austria200864► Subscribe
Poland191546► Subscribe
Brazil9713237► Subscribe
Iceland4964► Subscribe
Estonia9900090► Subscribe
China100335057► Subscribe
Hungary228007► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Concordia Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB97/078United Kingdom► SubscribePRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522
C0013France► SubscribePRODUCT NAME: DASABUVIR OU UN SEL DE CELUI-CI, NOTAMMENT LE SEL DE SODIUM; REGISTRATION NO/DATE: EU/1/14/983 20150119
C/GB02/037United Kingdom► SubscribePRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
666Luxembourg► SubscribePRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119
0443983/03Switzerland► SubscribePRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
14/032Ireland► SubscribePRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140121
C/GB98/030United Kingdom► SubscribePRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204
C0076France► SubscribePRODUCT NAME: SIMEPREVIR OU L'UN DE SES SELS, INCLUANT LE SEL DE SODIUM DE SIMEPREVIR; REGISTRATION NO/DATE: EU/1/14/924 20140514
C0021France► SubscribePRODUCT NAME: PEGAPTANIB SODIUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131
C0055France► SubscribePRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: 434323 20130220
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Baxter
AstraZeneca
Mallinckrodt
Cipla
Accenture
QuintilesIMS
Fish and Richardson
Healthtrust
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot